Skip to main content
    J

    Jaguar Animal Health Inc (JAGX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.39
    -0.03 (-7.74%)

    Market Cap: $5.59M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Jaguar Animal Health Inc (JAGX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 16, 2026. Financial statements from company filings, amounts in US dollars.

    Jaguar Animal Health reported revenue of $11.51M for the fiscal year ended Dec 31, 2025, down 1.5% from the year before. That year, net income was -$54.00M with a net margin of -469.1%, operating cash flow was -$23.69M and free cash flow was -$23.73M. The quarter ended Sep 30, 2026 had revenue of $2.34M and net income of -$5.83M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from $141.52K, a compound annual rate of 63.0%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$11.51M-1.5%67.2%-398.8%-469.1%
    Dec 2024$11.69M+19.8%83.3%-263.8%-335.8%
    Dec 2023$9.76M-18.4%79.1%-351.3%-429.3%
    Dec 2022$11.96M+175.8%83.1%-287.8%-404.8%
    Dec 2021$4.33M-53.8%46.2%-939.1%-1213.4%
    Dec 2020$9.38M+62.5%65.1%-283.9%-360.2%
    Dec 2019$5.78M+30.8%33.9%-501.3%-667.3%
    Dec 2018$4.42M+1.3%37.4%-698.0%-727.9%
    Dec 2017$4.36M+2981.6%79.8%-785.3%-503.7%
    Dec 2016$141.52KN/A63.3%-9599.8%-10410.9%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$11.51M$11.69M$9.76M$11.96M$4.33M$9.38M$5.78M$4.42M$4.36M$141.52K
    Cost of revenue$3.77M$1.96M$2.04M$2.02M$2.33M$3.28M$3.82M$2.77M$880.40K$51.97K
    Gross profit$7.74M$9.73M$7.72M$9.94M$2.00M$6.11M$1.96M$1.65M$3.48M$89.56K
    Research and development$24.97M$16.54M$18.60M$17.65M$15.08M$6.41M$5.82M$5.15M$4.27M$7.21M
    Operating income-$45.91M-$30.83M-$34.29M-$34.41M-$40.71M-$26.65M-$28.95M-$30.82M-$34.25M-$13.59M
    Net income-$54.00M-$39.25M-$41.90M-$48.40M-$52.60M-$33.81M-$38.54M-$32.15M-$21.97M-$14.73M
    EBITDAN/AN/A-$23.62M-$19.43M-$36.44M-$24.20M-$20.77M-$26.46M-$32.37M-$13.07M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$2.34M$1.23M$20.27M$3.23M$3.08M$2.98M$2.21M$3.51M$3.11M$2.72M$2.35M$2.30M
    Gross profit$1.72M$194.00K$19.11M$1.03M$2.55M$2.45M$1.70M$2.95M$2.57M$2.29M$1.92M$1.61M
    Operating income-$6.02M-$7.60M$10.18M-$21.24M-$7.24M-$8.01M-$9.42M-$8.16M-$7.26M-$7.20M-$8.21M-$7.56M
    Net income-$5.83M-$12.80M$8.72M-$23.19M-$9.65M-$10.56M-$10.60M-$10.23M-$10.02M-$9.63M-$9.37M-$9.31M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $42.52M exceeded cash and equivalents by $41.55M. Shareholder equity was negative, at -$17.29M, as total liabilities of $57.01M exceeded total assets of $38.32M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$38.32M$53.42M$50.76M$47.45M$53.27M$42.84M$36.41M$41.04M$43.63M$3.56M
    Current assets$20.34M$32.20M$27.96M$22.32M$28.43M$17.79M$9.52M$8.15M$3.80M$2.56M
    Cash and equivalents$968.00K$8.00M$6.47M$5.47M$17.05M$8.09M$3.50M$2.57M$520.70K$950.98K
    Total liabilities$57.01M$44.45M$45.87M$48.81M$41.41M$25.64M$15.84M$26.66M$26.37M$6.02M
    Short-term debt$27.44M$12.04M$4.87M$15.88M$3.18M$3.79M$6.78M$16.08M$5.42M$2.07M
    Long-term debt$15.08M$23.50M$30.99M$17.74M$25.02M$12.42M$450.00KN/A$10.98M$1.82M
    Shareholder equity-$17.29M$7.29M$4.96M-$657.00K$11.61M$17.20M$10.67M$5.38M$17.26M-$2.45M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$32.51M$34.19M$37.43M$38.32M$49.47M$48.27M$51.46M$53.42M$58.47M$61.46M$55.39M$50.76M
    Total liabilities$13.89M$29.27M$53.19M$57.01M$45.11M$41.39M$48.15M$46.93M$42.88M$42.40M$41.09M$45.87M
    Cash and equivalents$5.53M$3.79M$7.28M$968.00K$3.53M$2.21M$5.69M$8.00M$13.27M$16.05M$11.67M$6.47M
    Shareholder equity$20.32M$6.62M-$14.18M-$17.29M$5.63M$7.99M$1.78M$7.29M$13.61M$16.91M$12.00M$4.96M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$23.69M-$29.38M-$33.24M-$33.10M-$34.97M-$15.28M-$20.46M-$22.73M-$9.82M-$14.41M
    Capital expenditures$41.00K$16.00K$0$77.00K$6.00K$7.00K$0$6.53K$6.53K$104.21K
    Free cash flow-$23.73M-$29.40M-$33.24M-$33.18M-$34.98M-$15.29M-$20.46M-$22.74M-$9.83M-$14.52M
    Dividends paid$0$0$1.23M$0N/A$33.00KN/A$12.24M$0$0
    Share repurchasesN/AN/AN/AN/AN/AN/A$65.00KN/A$555.26KN/A
    Investing cash flow-$41.00K-$231.00K$0-$1.68M-$6.00K-$7.00K$0-$6.53K-$1.56M$2.38M
    Financing cash flow$23.67M$31.20M$34.23M$23.18M$43.94M$19.49M$21.77M$24.55M$10.68M$5.28M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$4.93M-$5.34M$8.83M-$5.49M-$4.69M-$6.20M-$7.31M-$7.83M-$6.34M-$8.17M-$7.05M-$7.45M
    Capital expendituresN/AN/A$29.00K$13.00K$54.00K$0$215.00K$215.00K$16.00K$16.00K$0$0
    Free cash flowN/AN/A$8.80M-$5.50M-$4.74M-$6.20M-$7.53M-$8.04M-$6.36M-$8.19M-$7.05M-$7.45M
    Last 12 quarters

    Frequently Asked Questions About JAGX

    What is Jaguar Animal Health's annual revenue?

    Jaguar Animal Health reported revenue of $11.51M for the fiscal year ended Dec 31, 2025.

    How fast is Jaguar Animal Health's revenue growing?

    Revenue was down 1.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -1.3%.

    Is Jaguar Animal Health profitable?

    No. Jaguar Animal Health reported net income of -$54.00M for the fiscal year ended Dec 31, 2025, with a net margin of -469.1%.

    How much free cash flow does JAGX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$23.69M minus capital expenditures of $41.00K produced free cash flow of -$23.73M.

    How much debt does Jaguar Animal Health have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $15.08M, short-term debt of $27.44M and cash and equivalents of $968.00K.